Hybryte™ expanded treatment trial in cutaneous t-cell lymphoma opens enrollment

Study supported by $2.6 million fda orphan products development grant princeton, n.j. , aug. 10, 2023 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that patient enrollment has been opened for the investigator-initiated study (iis) at the university of pennsylvania, supported by a $2.6 million orphan products development grant award by the u.s. food and drug administration (fda).
SNGX Ratings Summary
SNGX Quant Ranking